Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center

Bommannan, Karthik; Arumugam, Jhansi Rani; Radhakrishnan, Venkatraman; Kalaiyarasi, Jayachandran Perumal; Mehra, Nikita; Sagar, Tenali Gnana; Sundersingh, Shirley

doi:10.1016/j.htct.2020.08.012

Cited by 3 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 21 ] 1383 Outcomes in AYA ALL patients Patients treated with pediatric and adult protocols had no difference in their induction outcomes concerning the achievement of CR, induction mortality, or MRD positivity rate Bommannan et al . [ 22 ] 152 Clinical–pathological profiling of CD56- and CD7-expressing B-cell ALL patients Patients with high-risk disease and EOI MRD positivity were at higher risk of adverse events Das et al . [ 23 ] 239 Evaluating the expression of CD123 in acute leukemia, comparing it with post-induction morphologic complete remission and MRD status CD123 may be considered as a cardinal marker for: Residual disease assessment Response evaluation in AML and B-cell ALL Jain et al .…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the timings for assessment, five studies followed EOI assessments on days 29–33 [ 22 – 26 ], except for studies by Chatterjee et al . [ 32 ] and Das et al .…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the timings for assessment, five studies followed EOI assessments on days 29-33 [22][23][24][25][26], except for studies by Chatterjee et al [32] and Das et al [33] that made assessments between days 35 and 40 and 30 and 35, respectively [27]. Individual studies (n = 2) that evaluated at midinduction on day 21 or after phase 1a induction were also identified [27,28].…”

Section: Timing Of Mrd Assessmentmentioning

confidence: 99%

“…Patients with high-risk diseases and those with EOI MRD positivity are at higher risk of adverse events [22]. CD304 positivity has also been shown to be associated with BCR-ABL1 fusion, with a significant percentage of EOI and EOC MRD positivity [32].…”

Section: Risk Category and Mrd Statusmentioning

confidence: 99%

“…ity, or MRD positivity rate Bommannan et al[22] 152 Clinical-pathological profiling of CD56-and CD7-expressing B-cell…”

mentioning

confidence: 99%

See 4 more Smart Citations

Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings

Menon

Singh²,

Bagal

et al. 2023

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Minimal residual disease (MRD) has become an essential tool in the management of B-cell acute lymphoblastic leukemia (B-ALL) and aids in tailoring treatment strategies to suit specific patient needs. Although much progress has been made in this area, there is limited data on the use of MRD in the Indian context. Our objective was to identify relevant literature that discusses the utility of MRD in the management of B-cell ALL in adolescents and young adults (AYA) and adults in Indian settings. A systematic search and screening of articles were performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The primary data source was PubMed followed by Google Scholar for articles and conference proceedings. Of the 254 records screened, 24 records were retained for analysis. MRD monitoring had a significant role in the management of AYA/adult B-cell ALL patients. Variability of results was observed across these studies with respect to methods, techniques, and use. However, these studies evidenced and validated the importance of MRD assessment in risk-adapted management of B-cell ALL and highlighted the need for optimization. The advances in MRD diagnostics and applications are yet to be tested and adopted in Indian settings. Hence, there is a need for in-depth research to develop and optimize approaches for calibrating country-specific management strategies. The potential role of MRD assessments in anticipating relapse or treatment failures warrants more attention for the preemptive positioning of novel strategies involving immunotherapies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Regarding the timings for assessment, five studies followed EOI assessments on days 29–33 [ 22 – 26 ], except for studies by Chatterjee et al . [ 32 ] and Das et al .…”

Section: Resultsmentioning

confidence: 99%

Section: Timing Of Mrd Assessmentmentioning

confidence: 99%

Section: Risk Category and Mrd Statusmentioning

confidence: 99%

“…ity, or MRD positivity rate Bommannan et al[22] 152 Clinical-pathological profiling of CD56-and CD7-expressing B-cell…”

mentioning

confidence: 99%

See 3 more Smart Citations

Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings

Menon

Singh²,

Bagal

et al. 2023

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

IL-8 in bone marrow and peripheral blood of patients with B-cell acute lymphoblastic leukemia is associated with high regulatory T cell counts, degree of tumor infiltration and expression of CXCR1 in blasts

Anaya

Santander

Murillo

et al. 2024

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems

Krebs

Stech

Jorde

et al. 2022

IJMS

View full text Add to dashboard Cite

Recombinant immunotoxins (RITs) are an effective class of agents for targeted therapy in cancer treatment. In this article, we demonstrate the straight-forward production and testing of an anti-CD7 RIT based on PE24 in a prokaryotic and a eukaryotic cell-free system. The prokaryotic cell-free system was derived from Escherichia coli BL21 StarTM (DE3) cells transformed with a plasmid encoding the chaperones groEL/groES. The eukaryotic cell-free system was prepared from Chinese hamster ovary (CHO) cells that leave intact endoplasmic reticulum-derived microsomes in the cell-free reaction mix from which the RIT was extracted. The investigated RIT was built by fusing an anti-CD7 single-chain variable fragment (scFv) with the toxin domain PE24, a shortened variant of Pseudomonas Exotoxin A. The RIT was produced in both cell-free systems and tested for antigen binding against CD7 and cell killing on CD7-positive Jurkat, HSB-2, and ALL-SIL cells. CD7-positive cells were effectively killed by the anti-CD7 scFv-PE24 RIT with an IC50 value of 15 pM to 40 pM for CHO and 42 pM to 156 pM for E. coli cell-free-produced RIT. CD7-negative Raji cells were unaffected by the RIT. Toxin and antibody domain alone did not show cytotoxic effects on either CD7-positive or CD7-negative cells. To our knowledge, this report describes the production of an active RIT in E. coli and CHO cell-free systems for the first time. We provide the proof-of-concept that cell-free protein synthesis allows for on-demand testing of antibody–toxin conjugate activity in a time-efficient workflow without cell lysis or purification required.

show abstract

Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center

Cited by 3 publications

References 21 publications

Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings

Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings

IL-8 in bone marrow and peripheral blood of patients with B-cell acute lymphoblastic leukemia is associated with high regulatory T cell counts, degree of tumor infiltration and expression of CXCR1 in blasts

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems

Contact Info

Product

Resources

About